Skip to main content
. Author manuscript; available in PMC: 2015 May 1.
Published in final edited form as: Semin Oncol Nurs. 2014 May;30(2):109–116. doi: 10.1016/j.soncn.2014.03.004

FIGURE 1.

FIGURE 1

I-SPY 2 Schema trial design for I-SPY 2 (investigation of serial studies to predict your therapeutic response with imaging and molecular analysis 2). HER2, human epidermal growth factor receptor 2; MRI, magnetic resonance imaging; AC, anthracycline (doxo-rubicin) and cyclophosphamide (Cytoxan).